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Redeﬁning the Diagnosis of Diabetes
Using Glycated Hemoglobin
T
heworldwideepidemicoftype2di-
abetes continues unabated. Despite
extensive efforts to educate provid-
ers, patients, and even the public at large
astotheadvantagesofearlyidentiﬁcation
andtreatmenttopreventcomplications,a
large number of patients remain undiag-
nosed. A serious barrier to an enhanced
detection of diabetes has been inadequate
screening using tests somewhat inconve-
nient to patients and clinicians and there-
fore often not optimally implemented. In
this issue of Diabetes Care, a joint Ameri-
can Diabetes Association, International
Diabetes Federation, and European Asso-
ciation for the Study of Diabetes Interna-
tional Expert Committee examines
diagnostic testing for diabetes, speciﬁ-
cally, the role of A1C, and makes signiﬁ-
cant new recommendations. While this
report has not yet been endorsed as a
guideline by either of the associations (or
other organizations), it does represent a
step in that direction and thus deserves
attention.
Clearly, no clinical diagnostic test is
perfect.However,tobeclinicallyuseful,a
test must be accurate, speciﬁc, standard-
ized (or easily standardizable), handy,
and, ideally, inexpensive. While plasma
glucose testing meets some of these crite-
ria,itsusehasbeendoggedbytheneedto
obtain a sample in the fasting state (most
peopleattendtheiroutpatientvisitsinthe
fed state) or under standard carbohydrate
challengeconditions,i.e.,theoralglucose
tolerancetest.Therealsocontinuestobea
degree of uncertainty concerning the di-
agnostic performance of fasting glucose
testing versus that of the oral glucose
tolerance test—the latter done rarely in
clinical practice for obvious reasons: in-
convenience and cost. In addition, con-
siderable variability not only in 2-h
postglucoseloadvaluesbutalsoinfasting
glucose has been a problem. Appropri-
ately, clinicians have long wondered why
theycannotuseanotherdiagnosticindex,
such as A1C, an inherently attractive op-
tion because it recapitulates long-term
ambient glycemia as opposed to a single
point in time. With the recent introduc-
tion of the standardized global assay for
the measurement of A1C (1), greater ac-
curacy and precision than achieved with
plasmaglucosehavebeenpredicated.The
overalledgeofA1Coverplasmaglucoseis
accurately summarized in Table 1 of the
International Expert Committee’s report.
Importantly, the relation of A1C to
average glucose levels, while good, is not
perfect. On the other hand, it is conceiv-
able that this “glycation gap” (2) may ac-
tually offer an advantage in that it might
better predict the risk of complications in
individuals more susceptible to nonenzy-
matic glycation of a variety of proteins,
including those fundamentally important
to vascular biology. Nevertheless, we ex-
pect a signiﬁcant amount of controversy
in this regard.
Cost and lack of standardization of
the A1C test in some countries are likely
to be additional contentious issues fol-
lowing the recommendations of the
committee. The experts do, however,
recognize the difﬁculty and therefore en-
vision a reasonably balanced approach:
for those unable to obtain a standardized
A1C test (or an affordable one), to con-
tinue to use the well-established methods
of glucose testing—fasting and postchal-
lenge glucose—the older diagnostic crite-
riaofwhichwillremaininplace.Asimilar
approach should apply to individuals
with hemoglobinopathies or other disor-
ders of red cell life span, particularly com-
mon in certain ethnic groups, because A1C
measurement here may be unreliable (3).
There is likely to be some initial de-
bate concerning the cut point—A1C of
6.5%—chosentodeﬁnediabetes.Thisis,
of course, a problem whenever one co-
erces a diagnosis, which by deﬁnition
must be dichotomous, from a continuous
variable. Yet, one might argue that even
thefastingglucosethresholdof126mg/dl
(7 mmol/l), while not entirely arbitrary,
represents a point along a continuum of
metabolic derangement. Concern will be
compounded by the fact that the upper
limit of normal for A1C is 6.0%, leaving
something of a gray zone between this
value and the 6.5% cut point for diabetes.
Values herein are not quite normal and
yetnothighenoughtoqualifyasdiabetes.
This will predictably create the same con-
fusion that may have arisen in individuals
in the categories of impaired fasting glu-
cose and impaired glucose tolerance us-
ing the current guidelines. Moreover, the
sensitivity of the A1C test in this speciﬁc
range may be less than optimal. (In this
context, it is also very important to recog-
nize that point-of-care testing is not
recommended; the standardized assay,
which makes the new recommendations
feasible, is only available through a clini-
cal laboratory.)
The International Expert Committee
is indeed careful to point out that the
threshold does not identify an A1C level
below which risk is nil but, instead, one
below which risk is lower: an inﬂection
point in a continuous positive relation-
ship rather than a true step function.
However, the outcome used is retinopa-
thy,i.e.,oneofthemicrovascularcompli-
cations. It is natural to wonder whether a
different threshold might have been cho-
sen if the outcome considered had been
atherosclerotic cardiovascular disease
(CVD). Available data on the relationship
between A1C and CVD risk may be less
deﬁned than those relating to retinopathy
(4–6), but CVD events are more preva-
lent than microvascular events in type 2
diabetes (7–8). Admittedly, recent trial
results showing an uncertain link be-
tween lowering glucose and macrovascu-
larcomplicationsaddtothecomplexityof
deﬁningriskusingsolelyonefeature(i.e.,
glucose) of a multidimensional metabolic
disease(9–11).Itwouldbereassuringifa
criticalanalysisoftheevidenceconverged
onthesame—orveryclosetothesame—
A1C level to be posited as the diabetes
diagnosticthresholdcarryingdeﬁniterisk
for both micro- and macroangiopathy.
The lack of an A1C value for a formal
deﬁnition of “pre-diabetes” is likely to
raise further and related concerns. Here
again,othermethods,includingtheuseof
glucose values, may be helpful, but there
continues to be little consensus on the
best test to use in predicting diabetes. A
variety of mathematical models, ques-
tionnaires,andriskenginescanbeusedto
deﬁne risk of diabetes as well as risk of
cardiovascular disease, including one
availableontheAmericanDiabetesAssoci-
ation Web site (http://www.diabetes.org/
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rates of people with mildly abnormal tests
of glucose in the pre-diabetes range are
highlyvariable(12)anddysglycemiamay
sometimes regress to normal without in-
tervention. Even so, we expect consider-
able debate to follow with calls for a more
robust diagnostic option to detect at-risk
individuals. This is of particular impor-
tance when pharmacological therapy is
being considered. Critics may reason that
adiagnostictestforpopulation-basedand
societal interventions to eat healthy, in-
crease physical activity, and optimize
body weight is not necessary. Yet, we
would argue that when dealing with an
individual patient, the conversation re-
garding risk reduction, whether it is at-
tempted with diet or drugs, will be
facilitated with concrete numbers with
which a condition and its response to in-
tervention can be measured.
Finally, that the A1C diagnostic
threshold now being deﬁned at 6.5%
while the recommended target for most
diabetic patients remains at 7% will be
viewed by some as untidy—if not a con-
tradictionofsorts.However,goodclinical
judgment suggests that for many patients
it may be appropriate to start at least life-
style interventions whenever the diagno-
sis is made, irrespective of A1C. Whether
this threshold should now be considered
one for the initiation of metformin ther-
apy (or other agents) will be extremely,
and appropriately, controversial. The ar-
gument will not be settled until we have
randomized clinical trials that better in-
form our clinical decisions in patients
with such mild degrees of hyperglycemia.
Such data are sorely lacking at this point.
Indeed,clinicalresearchinthisarenamay
be easier to conduct now that the new
criteria have been suggested, given that
cases will be easier to identify at this early
stage.
In summary, the adoption of the A1C
test as a diagnostic criterion is a reason-
able proposition on the practical grounds
analyzed by the report. Its worldwide fea-
sibility is, at present, limited. In addition,
anchoring the diagnostic threshold solely
to microvascular risk, leaving a diagnostic
hiatus in the A1C range 6.1–6.5%, and
choosing an A1C threshold different from
thetreatmenttargetrecommendedbymost
guidelines (7%) are problematic aspects
carried over from the glucose-based diag-
nostics. Perhaps further analysis and rele-
vantnewevidencewillbeconsideredbefore
the ﬁndings and arguments of the Interna-
tional Expert Committee can be transposed
into widely endorsed recommendations.
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